Stay updated on Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial

Sign up to get notified when there's something new on the Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial page

  1. Check
    3 days ago
    Change Detected
    Summary
    The web page has been updated to indicate that the ClinicalTrials.gov data ingest will be modernized in June 2025, allowing API users to provide input before implementation. Additionally, the revision number has been updated from v2.15.2 to v2.16.1.
    Difference
    2%
    Check dated 2025-05-29T06:08:39.000Z thumbnail image
  2. Check
    10 days ago
    No Change Detected
  3. Check
    17 days ago
    No Change Detected
  4. Check
    31 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.15.0 to version 2.15.2.
    Difference
    0.1%
    Check dated 2025-04-30T14:17:51.000Z thumbnail image
  5. Check
    46 days ago
    Change Detected
    Summary
    The page has been updated to reflect a new version of the study protocol (v2.15.0) and includes the addition of specific cancer types and the collaborator's name, Merck Sharp & Dohme LLC. However, significant details regarding the study's purpose and treatment options have been removed.
    Difference
    51%
    Check dated 2025-04-16T09:52:00.000Z thumbnail image
  6. Check
    53 days ago
    Change Detected
    Summary
    The web page has been updated from version 2.14.3 to version 2.14.4.
    Difference
    0.1%
    Check dated 2025-04-09T04:51:55.000Z thumbnail image
  7. Check
    89 days ago
    Change Detected
    Summary
    The page has removed a notice regarding heavy traffic affecting the performance and availability of some NLM-NCBI services and products.
    Difference
    1%
    Check dated 2025-03-03T22:50:03.000Z thumbnail image
  8. Check
    110 days ago
    Change Detected
    Summary
    The web page now includes a notice about heavy traffic affecting the performance and availability of some NLM-NCBI services and products, along with contact information for assistance.
    Difference
    1%
    Check dated 2025-02-10T15:35:45.000Z thumbnail image

Stay in the know with updates to Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Pembrolizumab Combo in Neuroendocrine Carcinoma Clinical Trial page.